Markets:

Overview

News

Currencies

International

Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

74.76 -1.98 (-2.58%)

Streaming Delayed Price Updated: 1:49 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 19, 2023

Via Benzinga

NASDAQ:PTCT Shareholder Notice: Investigation over Possible Securities Laws Violations by PTC Therapeutics, Inc. ↗

October 10, 2023

San Diego, CA -- (SBWIRE) -- 10/10/2023 -- PTC Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 ↗

October 06, 2023

Via Benzinga

Expert Ratings for PTC Therapeutics ↗

September 19, 2023

Via Benzinga

Where PTC Therapeutics Stands With Analysts ↗

August 07, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 02, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

October 02, 2023

On Monday, 369 companies set new 52-week lows.

Via Benzinga

Raymond James Maintains Outperform Rating for PTC Therapeutics: Here's What You Need To Know ↗

August 04, 2023

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

Where PTC Therapeutics Stands With Analysts ↗

July 20, 2023

Via Benzinga

Dell Technologies To Rally More Than 15%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

September 19, 2023

Raymond James increased the price target for Vital Energy, Inc. (NYSE: VTLE) from $54 to $67. Raymond James analyst John Freeman maintained an Outperform rating. Vital Energy shares rose 0.5% to $54.37...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023 ↗

September 18, 2023

Via Benzinga

Morgan Stanley Maintains Equal-Weight Rating for PTC Therapeutics: Here's What You Need To Know ↗

July 11, 2023

Via Benzinga

What 15 Analyst Ratings Have To Say About PTC Therapeutics ↗

June 30, 2023

Via Benzinga

Micron Technology To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday ↗

September 18, 2023

Piper Sandler cut the price target for IBEX Limited (NASDAQ: IBEX) from $24 to $17. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. IBEX shares rose 0.3% to close at $13.59 on...

Via Benzinga

US Stock Futures Edge Higher Amid Cautious Optimism; Analyst Says How Fed Packages Sept. Pause Key For Market Direction ↗

September 18, 2023

US stock futures point to a higher opening on Monday after averages closed nearly flat in the week ended Sept. 15.

Via Benzinga

Topics Economy

European Authority Gives Thumbs Down To PTC Therapeutics' Duchenne Therapy; Analyst Says It Can Overturn The Challenge ↗

September 15, 2023

Friday morning, the Committee for Medicinal Products for Human Use of the European Medicines Agency gave a negative opinion on the conversion of the conditional marketing authorization to full...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 15, 2023

Via Benzinga

Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 15, 2023

Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results.

Via Benzinga

Nasdaq Down Over 1%; US Industrial Output Rises In August ↗

September 15, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% points on Friday. The Dow traded down 0.52% to 34,727.05 while the NASDAQ fell 1.31% to 13,743.78. The...

Via Benzinga

Topics Stocks

PTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On Friday ↗

September 15, 2023

U.S. stocks traded higher, with the Dow Jones falling around 180 points on Friday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Topics Stocks

Stocks That Hit 52-Week Lows On Friday ↗

September 15, 2023

Friday's session saw 169 companies set new 52-week lows.

Via Benzinga

Dow Dips 100 Points; US Export Prices Rise 1.3% In August ↗

September 15, 2023

U.S. stocks traded lower this morning, with the Dow Jones falling around 100 points on Friday. Following the market opening Friday, the Dow traded down 0.31% to 34,799.50 while the NASDAQ fell 1.09% to...

Via Benzinga

Topics Stocks

PTC Therapeutics Crashes 29% After European Regulators Reject Its Muscular Dystrophy Drug ↗

September 15, 2023

The company is working on a treatment for Duchenne muscular dystrophy.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023 ↗

September 15, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 15, 2023

Via Benzinga

Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases ↗

August 25, 2023

Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy.

Via InvestorPlace

PTC Therapeutics' Seizure Study Fails To Meet Primary Goal, Analyst Says Minimal Impact On Investment Thesis ↗

June 30, 2023

PTC Therapeutics Inc (NASDAQ: PTCT) said its MIT-E trial of vatiquinone for mitochondrial disease-associated seizures (MDAS) failed to achieve its primary endpoint of

Via Benzinga

PTC Therapeutics Says Interim Data For Huntington's Disease Candidate Shows Promise In Mid-Stage Study ↗

June 21, 2023

PTC Therapeutics Inc (NASDAQ: PTCT) shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in

Via Benzinga

3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs ↗

May 31, 2023

Small-cap stocks can be risky, and all three of these companies are facing adversity. But they could be home run investments.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.